×
About 20,058 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  7,042 results

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzh...
https://doi.org/10.1186/s13024-022-00566-4
Molecular Neurodegeneration; Fernández-Calle R, Konings SC et. al.

Sep 25th, 2022 - ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzhe...

Staufen impairs autophagy in neurodegeneration.
https://doi.org/10.1002/ana.26515
Annals of Neurology; Paul S, Dansithong W et. al.

Sep 25th, 2022 - The mechanistic target of rapamycin (mTOR) kinase is one of the master coordinators of cellular stress responses, regulating metabolism, autophagy, and apoptosis. We recently reported that Staufen1 (STAU1), a stress granule (SG) protein, was overa...

Intracellular energy controls dynamics of stress-induced ribonucleoprotein granules.
https://doi.org/10.1038/s41467-022-33079-1
Nature Communications; Wang T, Tian X et. al.

Sep 24th, 2022 - Energy metabolism and membraneless organelles have been implicated in human diseases including neurodegeneration. How energy deficiency regulates ribonucleoprotein particles such as stress granules (SGs) is still unclear. Here we identified a uniq...

Hyperosmolar Hyperglycemic Crisis After Burn Injury in a Patient With Advanced Amyotrop...
https://doi.org/10.1097/SAP.0000000000003293
Annals of Plastic Surgery; Lin MW, Chang YT et. al.

Sep 24th, 2022 - Metabolic disturbance in patients of amyotrophic lateral sclerosis is a rare presentation that might be related to disease progression and outcomes. Hypermetabolic status after major burn injury remains a critical issue in the modern medical care....

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, d...
https://doi.org/10.1111/ene.15573
European Journal of Neurology; Beghi E, Pupillo E et. al.

Sep 24th, 2022 - Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegene...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  538 results

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT04944784

Sep 22nd, 2022 - COURAGE-ALS is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS. The screening and qualification period for the trial will be no more than 14 days in duration. Approximately 555 eligib...

Delineating Swallowing Impairment and Decline in ALS
https://clinicaltrials.gov/ct2/show/NCT02962050

Sep 22nd, 2022 - This research study is being performed to determine screening tools or tests that are able to identify and track swallowing problems associated with Amyotrophic Lateral Sclerosis (ALS) over time. Also, this study will provide insight into the natu...

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB105 in Participants With Amyotrophic Lateral Sclerosis With or Without Poly-cytosine-adenine-guanine (CAG) Expansion in the A...
https://clinicaltrials.gov/ct2/show/NCT04494256

Sep 21st, 2022 - The primary objective is to evaluate the safety and tolerability of BIIB105 in participants with amyotrophic lateral sclerosis (ALS) or poly-CAG expansion (polyQ)-ALS. The secondary objective is to assess the pharmacokinetic (PK) profile of BIIB10...

Amyotrophic Lateral Sclerosis (ALS) Families Project
https://clinicaltrials.gov/ct2/show/NCT03865420

Sep 19th, 2022 - Approximately 10% of people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's Disease, have a family history of ALS or a related condition called frontotemporal dementia (FTD). In most of these familial cases, and a significant number of "...

Safety Study of Oral Edaravone Administered in Subjects With ALS
https://clinicaltrials.gov/ct2/show/NCT04165824

Sep 19th, 2022 - The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.

see more →

News  407 results

ALS Drug Yields Meaningful Clinical Benefit, Phase 3 Data Show
https://www.medscape.com/viewarticle/981466

Sep 27th, 2022 - Longer-term data show that the antisense oligonucleotide tofersen (Biogen) slows functional decline in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations. Combined 1-year data from the phase 3 ...

Serious Infections Linked to Early Alzheimer's, Parkinson's Disease
https://www.medscape.com/viewarticle/981175

Sep 21st, 2022 - Patients in early- and mid-life who contract with infections that require hospitalization appear to be at increased risk for neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD) at a relatively young age, new...

ALS Drug Gets FDA Panel Thumbs Up After Rare Second Look
https://www.medscape.com/viewarticle/980410

Sep 7th, 2022 - In a rare second review of a new drug application, a US Food and Drug Association (FDA) advisory panel has voted to recommend approval of a novel drug to treat amyotrophic lateral sclerosis (ALS). By a vote of 7-2, the FDA Peripheral and Central N...

FDA Still Skeptical of ALS Drug Ahead of High-Stakes Meeting
https://www.medscape.com/viewarticle/980270

Sep 6th, 2022 - WASHINGTON (AP) — Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig's disease, even as they prepare to give its drugmaker a rare second opportuni...

Hope, help, and humor when facing a life-threatening illness
https://www.mdedge.com/psychiatry/article/256621/hope-help-and-humor-when-facing-life-threatening-illness
Sarah D. Sosland, BS, Morton D. Sosland, MD

Aug 1st, 2022 - Editor’s note: Readers’ Forum is a department for correspondence from readers that is not in response to articles published in Current Psychiatry. All submissions to Readers’ Forum undergo peer review and are subject to editing for length and styl.

see more →

Patient Education  16 results see all →